A team in Pittsburgh received a $2.3 million grant to fast-track the development and clinical transition of a minimally ...

The US Food and Drug Administration (FDA) has granted Alleviant Medical an investigational device exemption (IDE), enabling the company to begin a pivotal trial evaluating its atrial shunt ...

The global hydrocephalus shunt market is poised for steady expansion, with Future Market Insights (FMI) projecting a market ...

Texas-based medical device company Alleviant has received a breakthrough device status from the US Food and Drug Administration (FDA) for its new no-implant atrial shunt for heart failure and will ...

USA: The recent RELIEVE-HF trial has revealed the efficacy of transcatheter interatrial shunt implantation as a treatment for ...

Wireless brain sensor aims to prevent failures, giving hydrocephalus patients early alerts before symptoms become critical.

CereVasc, Inc. announced the initial results of its United States pilot clinical study of the CereVasc eShunt system in the ...

a company dedicated to transforming the treatment of heart failure, announced today that it has achieved CE certification for the Corvia® Atrial Shunt System under the latest EU Medical Device ...